drugset / Trial / NCT03437070
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
NaSingle-groupOpen-labelTreatment
Summary
This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.
Timeline
- Start
- 2019-06
- Primary completion
- 2021-06
- Completion
- 2023-06
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Olaratumab | Monoclonal antibody | — | Intravenous |
| Subject | Trabectedin | Small molecule | — | Intravenous |